HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.720

-0.220-2.01%

Volume:647.50K

Turnover:6.67M

Market Cap:4.36B

PE:-12.06

High:10.720

Open:10.590

Low:10.090

Close:10.940

52wk High:246.000

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.19

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.889

ROE:-36.78%

ROA:-20.32%

PB:4.25

PE(LYR):-12.06

PS:105.17

Loading ...

Overview Company News Filings

TRANSTHERA-B Allocates HK$1.14 Million for Share Buyback on July 21

Transthera Sciences Files HKEX Next-day Disclosure Return After Share Repurchase for Treasury Shares

TRANSTHERA-B Announces Share Buyback Totaling HK$1.12 Million on July 20

Movement Alert｜Yaojie Ankang-B Declines 8.13% in Regular Trading, Trading at 9.83 HKD

TransThera's TT-00973 Cleared for China Phase 2 Lung Cancer Trial

MT Newswires Live

Transthera Sciences (nanjing) Says NMPA Approves Phase II Trial of Tt-973 with Firmonertinib Mesylate

TRANSTHERA-B Receives Regulatory Nod for Phase II Trial of TT-00973 in Combination with Furmonertinib for NSCLC

TransThera gains NMPA clearance to launch Phase II study of TT-00973 plus firmonertinib in EGFR-mutant NSCLC

Bulletin Express

Transthera Sciences (nanjing) - Nmpa Approves Phase Ii Trial of Tt-973 with Firmonertinib Mesylate on July 10, 2026

THOMSON REUTERS

Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib

Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan

Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval

From $270 Billion to $4.1 Billion: This Small Biotech, With Just Over 100 Employees, Is Undertaking What Giants Dare Not Attempt

Movement Alert｜TransThera Sciences Rises 6.93% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment and New Pipeline Gains Approval

TransThera Sciences Completes Patient Enrollment for Cholangiocarcinoma Drug Trial

MT Newswires Live

TRANSTHERA-B Secures Regulatory Approval for Phase II Trial of TT-01488 Combination Therapy in Mantle Cell Lymphoma

TransThera Sciences gains NMPA nod for Phase II study of BTK inhibitor TT-01488 plus anti-CD20 antibody in mantle cell lymphoma

Bulletin Express

TransThera Sciences Completes Enrollment for Global Phase III Tinengotinib Trial in Advanced Cholangiocarcinoma

Bulletin Express

Transthera Completes Enrollment in Phase III Tinengotinib Trial for Advanced Cholangiocarcinoma

Transthera Says China Regulator Clears Phase II Trial of Tt-01488 Combo in Mantle Cell Lymphoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/02617/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.72,"timestamp":1790928489006,"preClose":10.94,"halted":0,"volume":647500,"delay":0,"changeRate":-0.020109689213893864,"floatShares":312000000,"shares":407000000,"eps":-0.8892549868951771,"marketStatus":"Market Closed","change":-0.22,"latestTime":"10-02 16:08:09","open":10.59,"high":10.72,"low":10.09,"amount":6668120,"amplitude":0.057587,"askPrice":10.8,"askSize":1500,"bidPrice":10.45,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.7869602415211011,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.94,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"volumeRatio":0.187621,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.889255,"volumeRatio":0.187621,"shares":407000000,"dividePrice":0,"high":10.72,"amplitude":0.057587,"preClose":10.94,"low":10.09,"week52Low":9.01,"pbRate":"4.25","psRate":"105.17","week52High":246,"institutionHeld":0,"latestPrice":10.72,"committee":0.142857,"eps":-0.8892549868951771,"divideRate":0,"volume":647500,"delay":0,"ttmEps":-0.7869602415211011,"open":10.59,"prevYearClose":114.9,"prevWeekClose":10.03,"prevMonthClose":10.94,"prevQuarterClose":10.94,"fiveDayClose":10.33,"twentyDayClose":10.09,"sixtyDayClose":10.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-09-30","current":-13.622035,"percent":0.790476,"low":-380.446233,"twenty":-182.105406,"median":-69.048632,"eighty":-13.947457,"high":-10.87103,"avg":-105.736079,"sd":96.27792,"marketCap":4455518845},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-11","current":-12.187879,"twenty":-194.548173,"median":-71.729981,"eighty":-33.11771,"marketCap":3824237184},{"date":"2026-09-18","current":-13.02239,"twenty":-188.179892,"median":-71.163303,"eighty":-16.078674,"marketCap":4091423888},{"date":"2026-09-25","current":-13.026466,"twenty":-182.801065,"median":-69.75013,"eighty":-14.040359,"marketCap":4084904388},{"date":"2026-09-30","current":-14.181871,"twenty":-182.105406,"median":-69.048632,"eighty":-13.947457,"marketCap":4455518845}],"updateTime":1790964199936},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151207063","title":"TRANSTHERA-B Allocates HK$1.14 Million for Share Buyback on July 21","url":"https://stock-news.laohu8.com/highlight/detail?id=1151207063","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151207063?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:20","pubTimestamp":1784636418,"startTime":"0","endTime":"0","summary":"The biopharmaceutical company TRANSTHERA-B (02617) has announced the execution of a share repurchase transaction.On July 21, 2026, the firm utilized approximately HK$1.14 million to buy back 111,000 of its own shares.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277375","title":"Transthera Sciences Files HKEX Next-day Disclosure Return After Share Repurchase for Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277375","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277375?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:17","pubTimestamp":1784636226,"startTime":"0","endTime":"0","summary":"Transthera Sciences files HKEX next-day disclosure return after share repurchase for treasury sharesTransthera Sciences (Nanjing) repurchased 111,000 H shares on July 21, 2026 for treasury at HKD 9.92","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDLbqgZBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194027454","title":"TRANSTHERA-B Announces Share Buyback Totaling HK$1.12 Million on July 20","url":"https://stock-news.laohu8.com/highlight/detail?id=1194027454","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194027454?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:30","pubTimestamp":1784543419,"startTime":"0","endTime":"0","summary":"On July 20, 2026, TRANSTHERA-B (02617) executed a share repurchase, utilizing approximately HK$1.12 million to acquire 112,000 of its own shares.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136767784","title":"Movement Alert｜Yaojie Ankang-B Declines 8.13% in Regular Trading, Trading at 9.83 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1136767784","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136767784?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:37","pubTimestamp":1784255879,"startTime":"0","endTime":"0","summary":"On July 17, Yaojie Ankang-B (02617.HK) fell 8.13% in regular trading, trading at 9.83 HKD/share, with turnover of approximately 60.28 million HKD.Within the Biotechnology sector where Yaojie Ankang-B...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651716009","title":"TransThera's TT-00973 Cleared for China Phase 2 Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651716009","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651716009?lang=en_us&edition=fundamental","pubTime":"2026-07-13 12:01","pubTimestamp":1783915285,"startTime":"0","endTime":"0","summary":"TransThera Sciences  said China's National Medical Products Administration approved a Phase 2 clinical trial of its TT-00973 tablets in combination with firmonertinib mesylate, according to a July 10 Hong Kong bourse filing.The combination will be evaluated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR-sensitive mutations.The multi-center, open-label study will assess the safety and efficacy of the combination therapy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IE0004091025.USD","IE00BZ1G4Q59.USD","LU2552382132.HKD","IE00B3CCJ633.GBP","LU0795875086.SGD","LU2211814178.USD","LU2463526074.USD","LU2764263039.SGD","TT","LU2279689827.SGD","LU0726765562.USD","LU2552382058.USD","LU0070217475.USD","LU2394011477.USD","IE00BGHQF417.EUR","IE00BKVL7J92.USD","LU0238689110.USD","IE00B2PGVK34.USD","LU2229751404.USD","LU2347655073.USD","BK4504","LU2720916845.USD","BK4585","SG9999002232.USD","BK1161","LU1732800096.USD","LU0323240290.USD","LU0795875169.SGD","LU1732799900.SGD","LU2211817866.USD","LU0912757837.SGD","LU2764263203.CNY","LU1718418525.SGD","LU0154245756.USD","LU2552382215.SGD","LU0210533765.USD","LU0323239441.USD","LU2764262908.HKD","IE0004086264.USD","02617","LU2347655156.SGD","SG9999002224.SGD","LU2133065610.SGD","LU0154245673.USD","LU2089279066.USD","BK4533","BK4086","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2650378139","title":"Transthera Sciences (nanjing) Says NMPA Approves Phase II Trial of Tt-973 with Firmonertinib Mesylate","url":"https://stock-news.laohu8.com/highlight/detail?id=2650378139","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650378139?lang=en_us&edition=fundamental","pubTime":"2026-07-10 23:31","pubTimestamp":1783697473,"startTime":"0","endTime":"0","summary":"July 10 (Reuters) - TransThera Sciences (Nanjing) Inc <2617.HK>::*NMPA APPROVES PHASE II TRIAL OF TT-973 WITH FIRMONERTINIB MESYLATE ON JULY 10, 2026*Further company coverage: 2617.HK* ((Reuters.Brief","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nRSD5nKzfH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167220060","title":"TRANSTHERA-B Receives Regulatory Nod for Phase II Trial of TT-00973 in Combination with Furmonertinib for NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1167220060","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167220060?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:24","pubTimestamp":1783693470,"startTime":"0","endTime":"0","summary":"Clinical trial approval has been granted for a Phase II study of TRANSTHERA-B's (ASX: 02617) investigational drug TT-00973 in combination with furmonertinib for a specific type of lung cancer.The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE0004091025.USD","IE00BZ1G4Q59.USD","LU2552382132.HKD","IE00B3CCJ633.GBP","LU0795875086.SGD","LU2211814178.USD","LU2463526074.USD","LU2764263039.SGD","TT","LU2279689827.SGD","LU0726765562.USD","LU2552382058.USD","LU0070217475.USD","LU2394011477.USD","IE00BGHQF417.EUR","IE00BKVL7J92.USD","LU0238689110.USD","IE00B2PGVK34.USD","LU2229751404.USD","LU2347655073.USD","BK4504","LU2720916845.USD","BK4585","SG9999002232.USD","IBBQ","BK1161","LU1732800096.USD","LU0323240290.USD","LU0795875169.SGD","BMED","LU1732799900.SGD","LU2211817866.USD","LU0912757837.SGD","LU2764263203.CNY","LU1718418525.SGD","LU0154245756.USD","LU2552382215.SGD","LU0210533765.USD","LU0323239441.USD","LU2764262908.HKD","IE0004086264.USD","02617","LU2347655156.SGD","SG9999002224.SGD","LU2133065610.SGD","LU0154245673.USD","LU2089279066.USD","BK4533","BK4086","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184982898","title":"TransThera gains NMPA clearance to launch Phase II study of TT-00973 plus firmonertinib in EGFR-mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1184982898","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184982898?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:23","pubTimestamp":1783693419,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera, HKEX: 02617) has secured National Medical Products Administration approval, dated 10 July 2026, to initiate a multi-centre, open-label Phase II trial...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135665","title":"Transthera Sciences (nanjing) - Nmpa Approves Phase Ii Trial of Tt-973 with Firmonertinib Mesylate on July 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650135665?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:18","pubTimestamp":1783693085,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C0FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185228112","title":"Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1185228112","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185228112?lang=en_us&edition=fundamental","pubTime":"2026-07-10 11:12","pubTimestamp":1783653127,"startTime":"0","endTime":"0","summary":"On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.On the news front, the company announced on July 1 that its core product...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135423515","title":"Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1135423515","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135423515?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:30","pubTimestamp":1783305047,"startTime":"0","endTime":"0","summary":"On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103684444","title":"Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1103684444","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103684444?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:51","pubTimestamp":1783043474,"startTime":"0","endTime":"0","summary":"On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127655442","title":"From $270 Billion to $4.1 Billion: This Small Biotech, With Just Over 100 Employees, Is Undertaking What Giants Dare Not Attempt","url":"https://stock-news.laohu8.com/highlight/detail?id=1127655442","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127655442?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:27","pubTimestamp":1782984462,"startTime":"0","endTime":"0","summary":"The market valuation of TRANSTHERA-B (02617) has plummeted from a historical peak of HK$270 billion to approximately HK$4.1 billion. On June 23rd, the company entered the second phase of a post-IPO...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156797201","title":"Movement Alert｜TransThera Sciences Rises 6.93% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment and New Pipeline Gains Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1156797201","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156797201?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:25","pubTimestamp":1782959132,"startTime":"0","endTime":"0","summary":"On July 2, TransThera Sciences-B (02617.HK) rose 6.93% in regular trading, reaching HK$12.29 per share, with turnover of HK$317 million.On the news front, the company released two R&D progress...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648543329","title":"TransThera Sciences Completes Patient Enrollment for Cholangiocarcinoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648543329","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648543329?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:32","pubTimestamp":1782909170,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) (HKG:2617) completed enrollment for a phase III trial of Tinengotinib.The drug is being tested for the treatment of patients with advanced cholangiocarcinoma, according to a Wednesday Hong Kong bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165007087","title":"TRANSTHERA-B Secures Regulatory Approval for Phase II Trial of TT-01488 Combination Therapy in Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1165007087","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165007087?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:38","pubTimestamp":1782905913,"startTime":"0","endTime":"0","summary":"The China National Medical Products Administration (NMPA) has granted approval for a Phase II clinical trial of TRANSTHERA-B's (ASX: 02617) product, TT-01488 tablets, in combination with an anti-CD20...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655073.USD","BK1161","01488","IE00B2PGVK34.USD","LU0210533765.USD","BK4086","LU2229751404.USD","BK4533","LU2764263203.CNY","IE00BKVL7J92.USD","LU0795875169.SGD","LU2089279066.USD","LU2720916845.USD","IE00BZ1G4Q59.USD","BK1233","LU2133065610.SGD","LU0912757837.SGD","LU2552382058.USD","IE00BGHQF417.EUR","BK4585","LU0070217475.USD","LU0795875086.SGD","LU0323239441.USD","IE0004091025.USD","LU0266013472.USD","02617","LU0154245756.USD","LU2463526074.USD","LU2552382215.SGD","LU0323240290.USD","BK4588","LU1718418525.SGD","LU2211817866.USD","SG9999002224.SGD","LU2211814178.USD","IE0004086264.USD","LU2279689827.SGD","BK4504","IE00B3CCJ633.GBP","LU1732799900.SGD","LU2552382132.HKD","TT","SG9999002232.USD","LU2394011477.USD","LU2764262908.HKD","LU1732800096.USD","LU0726765562.USD","LU0238689110.USD","LU2347655156.SGD","LU0154245673.USD","LU2764263039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154644853","title":"TransThera Sciences gains NMPA nod for Phase II study of BTK inhibitor TT-01488 plus anti-CD20 antibody in mantle cell lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1154644853","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154644853?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:25","pubTimestamp":1782905141,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Stock Name: TRANSTHERA-B) announced that China’s National Medical Products Administration granted approval on 1 July 2026 for a Phase II clinical trial evaluating TT-01488...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134347564","title":"TransThera Sciences Completes Enrollment for Global Phase III Tinengotinib Trial in Advanced Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1134347564","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134347564?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:25","pubTimestamp":1782905102,"startTime":"0","endTime":"0","summary":"TransThera Sciences (TRANSTHERA-B, 02617) announced the completion of patient enrollment for its global, multicenter, registrational Phase III study evaluating Tinengotinib (TT-00420) monotherapy in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648179985","title":"Transthera Completes Enrollment in Phase III Tinengotinib Trial for Advanced Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2648179985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648179985?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:11","pubTimestamp":1782904317,"startTime":"0","endTime":"0","summary":"TransThera completes enrollment in Phase III tinengotinib trial for advanced cholangiocarcinomaTransthera Sciences (Nanjing) completed enrollment in a global, registrational Phase III trial of tinengo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL7yf7Yr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648173425","title":"Transthera Says China Regulator Clears Phase II Trial of Tt-01488 Combo in Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2648173425","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648173425?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:04","pubTimestamp":1782903848,"startTime":"0","endTime":"0","summary":"TransThera says China regulator clears Phase II trial of TT-01488 combo in mantle cell lymphomaTransthera Sciences received China NMPA clearance on July 1, 2026 to start a Phase II trial of TT-01488 t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL6bFrgH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":134,"code":"91000000","status":"200"}]}}